A cross-sectional observational study of the prevalence and characterization of potential QT-prolonging drug‒drug interactions in oncological outpatients.

Q3 Pharmacology, Toxicology and Pharmaceutics

Journal of Basic and Clinical Physiology and Pharmacology Pub Date : 2025-08-12 DOI:10.1515/jbcpp-2024-0104

Akash Agnihotri, Biswadeep Das, Sachin Manocha, Manjunath Bidarolli, Bharati Vashisht

{"title":"A cross-sectional observational study of the prevalence and characterization of potential QT-prolonging drug‒drug interactions in oncological outpatients.","authors":"Akash Agnihotri, Biswadeep Das, Sachin Manocha, Manjunath Bidarolli, Bharati Vashisht","doi":"10.1515/jbcpp-2024-0104","DOIUrl":null,"url":null,"abstract":"Objectives: This study aims to assess the prevalence, characteristics, and risk factors of potential QT-prolonging drug-drug interactions (pQT-DDIs) in cancer patients, including identifying drug combinations contributing to QT prolongation and key predictors.Methods: In this hospital-based, cross-sectional observational study, all types of cancer patients, irrespective of age or sex, were included over 1 year. pQT-DDIs were identified using four drug interaction checker software tools. Predictors were analyzed using univariate logistic regression.Results: A total of 1,331 cancer patients were included. The prevalence of pQT-DDIs was 67.6 %. Of these, 606 (45.5 %) had 1-2 pQT-DDIs, 126 (9.5 %) had 3-4, and 78 (5.9 %) had 5-6. Overall, 163 drug combinations were identified as causing QT prolongation; 122 were detected by Drugs.com. Significant predictors included >8 drugs prescribed (OR=6.46; CI=4.87-8.56; p<0.0001), >2 anticancer drugs (OR=1.68; CI=1.14-2.46; p=0.008), >6 adjuvant drugs (OR=6.83; CI=5.17-9.03; p<0.0001), solid cancers (OR=6.59; CI=4.59-8.80; p<0.0001), and cytotoxic drug use (OR=2.40; CI=1.52-3.77; p=0.0001).Conclusions: There is a high prevalence of pQT-DDIs in cancer patients. Those receiving multiple anticancer and adjuvant drugs are at higher risk. Routine interaction screening is recommended before chemotherapy.","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Basic and Clinical Physiology and Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/jbcpp-2024-0104","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: This study aims to assess the prevalence, characteristics, and risk factors of potential QT-prolonging drug-drug interactions (pQT-DDIs) in cancer patients, including identifying drug combinations contributing to QT prolongation and key predictors.

Methods: In this hospital-based, cross-sectional observational study, all types of cancer patients, irrespective of age or sex, were included over 1 year. pQT-DDIs were identified using four drug interaction checker software tools. Predictors were analyzed using univariate logistic regression.

Results: A total of 1,331 cancer patients were included. The prevalence of pQT-DDIs was 67.6 %. Of these, 606 (45.5 %) had 1-2 pQT-DDIs, 126 (9.5 %) had 3-4, and 78 (5.9 %) had 5-6. Overall, 163 drug combinations were identified as causing QT prolongation; 122 were detected by Drugs.com. Significant predictors included >8 drugs prescribed (OR=6.46; CI=4.87-8.56; p<0.0001), >2 anticancer drugs (OR=1.68; CI=1.14-2.46; p=0.008), >6 adjuvant drugs (OR=6.83; CI=5.17-9.03; p<0.0001), solid cancers (OR=6.59; CI=4.59-8.80; p<0.0001), and cytotoxic drug use (OR=2.40; CI=1.52-3.77; p=0.0001).

Conclusions: There is a high prevalence of pQT-DDIs in cancer patients. Those receiving multiple anticancer and adjuvant drugs are at higher risk. Routine interaction screening is recommended before chemotherapy.

查看原文本刊更多论文

肿瘤门诊患者中潜在延长qt的药物-药物相互作用的患病率和特征的横断面观察研究。

目的：本研究旨在评估癌症患者中潜在延长QT间期的药物-药物相互作用（pqt - ddi）的患病率、特征和危险因素，包括确定导致QT间期延长的药物组合和关键预测因素。方法：在这项以医院为基础的横断面观察性研究中，所有类型的癌症患者，无论年龄或性别，均纳入1年以上。使用四种药物相互作用检查软件工具鉴定pqt - ddi。预测因子采用单变量逻辑回归分析。结果：共纳入1331例肿瘤患者。pqt - ddi患病率为67.6% %。其中606例（45.5% %）有1-2个pqt - ddi， 126例（9.5% %）有3-4个，78例（5.9% %）有5-6个。总的来说，163种药物组合被确定为引起QT延长；Drugs.com检测到122种。显著预测因子包括：bbbb8种药物处方(OR=6.46；CI = 4.87 - -8.56;p2类抗癌药物(OR=1.68；CI = 1.14 - -2.46;p=0.008)、bbb6辅助用药(OR=6.83；CI = 5.17 - -9.03;结论：肿瘤患者中pqt - ddi的发生率较高。接受多种抗癌和辅助药物治疗的患者风险更高。化疗前建议进行常规相互作用筛查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Basic and Clinical Physiology and Pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.90

自引率

0.00%

发文量

期刊介绍： The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including brain research; cardiovascular-pulmonary interactions; exercise; thermal control; haematology; immune response; inflammation; metabolism; oxidative stress; and phytotherapy. As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes. Topics: Behavior and Neuroprotection, Reproduction, Genotoxicity and Cytotoxicity, Vascular Conditions, Cardiovascular Function, Cardiovascular-Pulmonary Interactions, Oxidative Stress, Metabolism, Immune Response, Hematological Profile, Inflammation, Infection, Phytotherapy.